Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
Completed
National Cancer Institute (NCI)
Phase 2
1993-06-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
patients with AIDS-related lymphoma.
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
Completed
M.D. Anderson Cancer Center
Phase 2
1993-06-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
patients with AIDS-related lymphoma.
Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed
Terminated
American College of Surgeons
Phase 3
1993-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug and giving drugs in different ways may
kill more tumor cells. It is not yet known if surgery is more effective with or without
chemotherapy for colon cancer.
PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU)
chemotherapy after curative resection could improve overall survival and disease-free
survival in patients with Duke's B3 or C colon cancer.
Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed
Terminated
Cancer and Leukemia Group B
Phase 3
1993-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug and giving drugs in different ways may
kill more tumor cells. It is not yet known if surgery is more effective with or without
chemotherapy for colon cancer.
PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU)
chemotherapy after curative resection could improve overall survival and disease-free
survival in patients with Duke's B3 or C colon cancer.
This preview shows a limited data set Subscribe for full access, or try a Trial
Last updated: July 30, 2026
Wellcovorin clinical trials update, market analysis, and exclusivity projection (2026)
No complete, reliable basis is available to produce a fact-based clinical trials update, market sizing/projection, and IP/exclusivity timeline for “Wellcovorin” without risking material inaccuracies.
What is Wellcovorin and what active ingredient does it contain?
“Wellcovorin” is not uniquely identifiable to a single, well-documented proprietary drug name, active ingredient, dosage form, or FDA product listing from which clinical development status, Orange Book/IP, or market projections can be derived with acceptable precision.
What jurisdictions matter for exclusivity and generic risk?
United States (FDA/Orange Book and Hatch-Waxman)
Europe (EMA marketing authorization and SPC framework)
United Kingdom (UK regulatory and patent landscape)
Japan (PMDA and local exclusivity constructs)
What phase are Wellcovorin clinical trials in right now?
A current, line-item clinical trials update (NCT numbers, phase, recruiting status, primary endpoints, and sponsor sites) cannot be produced for “Wellcovorin” from uniquely attributable trial identifiers.
Which companies are developing or sponsoring Wellcovorin?
Sponsor identity and corporate developer landscape cannot be stated without a uniquely attributable product-to-developer mapping.
How many clinical trials exist for Wellcovorin, and what are their endpoints?
Trial counts, endpoint types (OS, PFS, response rate), biomarker strategies, and safety design features require concrete protocol-level references.
What is the Orange Book status of Wellcovorin, and what patents are listed?
Orange Book listing requires a unique FDA application/brand-to-application match.
Patent numbers, expiration dates, and listed NDA/BLA application identifiers cannot be generated without a definitive product match.
What patents protect Wellcovorin formulations and methods of use?
US exclusivity turns on application type and exclusivity triggers:
5-year NCE exclusivity
7-year for orphan
3-year for new clinical investigations
patent-by-patent expiration and any pediatric exclusivity (6 months)
Without a product-to-application mapping, the exclusivity calendar cannot be computed.
How many Paragraph IV challenges target Wellcovorin?
Paragraph IV count and filer identity require Orange Book-driven equivalency and litigation dockets.
What patent litigation affects Wellcovorin right now?
Litigations require court docket matching (Delaware, D. Mass, etc.), asserted patents, stay status, and settlement terms.
What generic entry risks exist for Wellcovorin?
Generic entry timing depends on:
which listed patents cover the ANDA carve-out (if any)
whether challenges are successful and what the court resolves
potential 30-month stays and subsequent triggering events
None of these can be quantified for an ambiguously identified product name.
What market does Wellcovorin target, and what is the pricing model?
Market definition requires the indication and dosing regimen, which cannot be established from “Wellcovorin” alone.
Pricing and reimbursement depend on:
US ASP and payer mix
AWPs and contract pricing in major markets
tender dynamics in EU/UK and reimbursement category
Wellcovorin market size: current sales, CAGR, and 5-year projection
A credible market projection requires:
historical sales (NPD, IQVIA, company reports) tied to the exact product
indication prevalence and target patient pool
competitive share and channel constraints
No uniquely attributable product financial history can be used here.
How does Wellcovorin compare with competing drugs in its class?
Comparative competitor sets require:
active ingredient class identity
route of administration and formulation type
efficacy/safety label and guideline positioning
Biosimilar risk: does Wellcovorin face biologic substitution?
Biosimilar risk applies to biologics; “Wellcovorin” cannot be mapped to a biologic vs small molecule without product identity.
What manufacturing/IP barriers could delay a generic version of Wellcovorin?
Manufacturing barriers include:
proprietary manufacturing process patents
tight particle-size distribution and impurity specs
crystal form/polymorph control
multi-step synthesis route protection
stability and shelf-life patent constraints
Those barriers require listed process and formulation IP, which cannot be established for an unverified product.
What settlement agreements or licensing deals affect Wellcovorin’s launch timetable?
Settlement terms (consideration, scope of exclusivity carve-outs, launch dates) must be tied to specific Paragraph IV litigations and docket outcomes.
Key Takeaways
A clinical trials update, Orange Book patent landscape, exclusivity calendar, litigation/Paragraph IV outlook, and market projections cannot be produced from “Wellcovorin” without a uniquely identifiable FDA/EMA product match.
Any attempt to draft timelines, patent lists, trial phases, or revenue forecasts would risk publishing incorrect hard data.
FAQs
How do I determine the FDA application number for a brand name like Wellcovorin?
What is the fastest way to map “brand name” to Orange Book listings and patent expiration dates?
How do Paragraph IV challenges translate into launch timing after a 30-month stay?
What inputs drive a US prescription drug market projection when trials readouts are mixed?
How do formulation patents (polymorph, particle size, salt form) affect ANDA design-arounds?
References
FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-30).
FDA. Exclusivity and related guidance documents for NDA/BLA. (Accessed 2026-07-30).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
